Khalid Bajou

Khalid Bajou

Auto-generated profile, based on publicly available information

Khalid Bajou

Department of Applied Biology, College of Sciences, University of Sharjah, Sharjah, United Arab Emirates

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1998 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KBK. Bajou
K. Bajou
ANAgnes Noel
Agnes Noel
RGR.D. Gerard
R.D. Gerard
VMV. Masson
V. Masson
NBN. Brunner
N. Brunner
JFJ.M. Foidart
J.M. Foidart

19 February 2001 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
KBKhalid Bajou
Khalid Bajou
VMVéronique Masson
Véronique Masson
RGRobert D. Gerard
Robert D. Gerard
PSPetra M. Schmitt
Petra M. Schmitt
VAValérie Albert
Valérie Albert
ANAgnes Noel
Agnes Noel
The plasminogen (Plg)/plasminogen activator (PA) system plays a key role in cancer progression, presumably via mediating extracellular matrix degradation and tumor cell migration. Consequently, urokinase-type PA (uPA)/plasmin antagonists are currently being developed for suppression of tumor growth and angiogenesis. Paradoxically, however, high levels of PA inhibitor 1 (PAI-1) are predictive of a poor prognosis for survival of patients with cancer. We demonstrated previously that PAI-1 promoted tumor angiogenesis, but by an unresolved mechanism. We anticipated that PAI-1 facilitated endothelial cell migration via its known interaction with vitronectin (VN) and integrins. However, using adenoviral gene transfer of PAI-1 mutants, we observed that PAI-1 promoted tumor angiogenesis, not by interacting with VN, but rather by inhibiting proteolytic activity, suggesting that excessive plasmin proteolysis prevents assembly of tumor vessels. Single deficiency of uPA, tissue-type PA (tPA), uPA receptor, or VN, as well as combined deficiencies of uPA and tPA did not impair tumor angiogenesis, whereas lack of Plg reduced it. Overall, these data indicate that plasmin proteolysis, even though essential, must be tightly controlled during tumor angiogenesis, probably to allow vessel stabilization and maturation. These data provide insights into the clinical paradox whereby PAI-1 promotes tumor progression and warrant against the uncontrolled use of uPA/plasmin antagonists as tumor angiogenesis inhibitors.

1 February 2002 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
LDLaetitia Devy
Laetitia Devy
SBSilvia Blacher
Silvia Blacher
CGChristine Grignet-Debrus
Christine Grignet-Debrus
KBKhalid Bajou
Khalid Bajou
VMVéronique Masson
Véronique Masson
JFJean-Michel Foidart
Jean-Michel Foidart
Plasminogen activator inhibitor 1 (PAI‐1) is believed to control proteolytic activity and cell migration during angiogenesis. We previously demonstrated in vivo that this inhibitor is necessary for optimal tumor invasion and vascularization. We also showed that PAI‐1 angiogenic activity is associated with its control of plasminogen activation but not with the regulation of cell‐matrix interaction. To dissect the role of the various components of the plasminogen activation system during angiogenesis, we have adapted the aortic ring assay to use vessels from gene‐inactivated mice. The single deficiency of tPA, uPA, or uPAR, as well as combined deficiencies of uPA and tPA, did not dramatically affect microvessel formation. Deficiency of plasminogen delayed microves‐sel outgrowth. Lack of PAI‐1 completely abolished angio‐genesis, demonstrating its importance in the control of plasmin‐mediated proteolysis. Microvessel outgrowth from PAI‐1 ‐/‐ aortic rings could be restored by adding exogenous PAI‐1 (wild‐type serum or purified recombi‐nant PAI‐1). Addition of recombinant PAI‐1 led to a bell‐shaped angiogenic response clearly showing that PAI‐1 is proangiogenic at physiological concentrations and antiangiogenic at higher levels. Using specific PAI‐1 mutants, we could demonstrate that PAI‐1 promotes an‐giogenesis at physiological (nanomolar) concentrations through its antiproteolytic activity rather than by interacting with vitronectin.—Devy, L., Blacher, S., Grignet‐Debrus, C., Bajou, K., Masson, V., Gerard, R. D., Gils, A., Carmeliet, G., Carmeliet, P., Declerck, P. J., Noèl, A., Foidart, J. M. The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 16, 147–154 (2002)

24 March 1997 in FEBS Letters
Verified
Journal Article
Closed access
EBE.N. Baramova
E.N. Baramova
KBK. Bajou
K. Bajou
ARA. Remacle
A. Remacle
CLC. L'HOir
C. L'HOir
HKH.W. Krell
H.W. Krell
JFJ.M. Foidart
J.M. Foidart

2 August 2004 in Oncogene
Verified
Journal Article
Closed access
KBKhalid Bajou
Khalid Bajou
CMCatherine Maillard
Catherine Maillard
MJMaud Jost
Maud Jost
RLRoger H Lijnen
Roger H Lijnen
AGAnn Gils
Ann Gils
ANAgnes Noel
Agnes Noel

18 November 2004 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
VMVéronique Masson
Véronique Masson
LBLaura Rodriguez De La Ballina
Laura Rodriguez De La Ballina
CMCarine Munaut
Carine Munaut
Ben WielockxBen Wielockx
Ben Wielockx
MJMaud Jost
Maud Jost
ANAgnes Noel
Agnes Noel
The matrix metalloproteinases (MMPs) play a key role in normal and pathological angiogenesis by mediating extracellular matrix degradation and/or controlling the biological activity of growth factors, chemokines, and/or cytokines. Specific functions of individual MMPs as anti‐ or proangiogenic mediators remain to be elucidated. In the present study, we assessed the impact of single or combined MMP deficiencies in in vivo and in vitro models of angiogenesis (malignant keratinocyte transplantation and the aortic ring assay, respectively). MMP‐9 was predominantly expressed by neutrophils in tumor transplants, whereas MMP‐2 and MMP‐3 were stromal. Neither the single deficiency of MMP‐2, MMP‐3, or MMP‐9, nor the combined absence of MMP‐9 and MMP‐3 did impair tumor invasion and vascularization in vivo. However, there was a striking cooperative effect in double MMP‐2:MMP‐9‐deficient mice as demonstrated by the absence of tumor vascularization and invasion. In contrast, the combined lack of MMP‐2 and MMP‐9 did not impair the in vitro capillary outgrowth from aortic rings. These results point to the importance of a cross talk between several host cells for the in vivo tumor promoting and angiogenic effects of MMP‐2 and MMP‐9. Our data demonstrate for the first time in an experimental model that MMP‐2 and MMP‐9 cooperate in promoting the in vivo invasive and angiogenic phenotype of malignant keratinocytes.